JP2016521987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521987A5 JP2016521987A5 JP2016520422A JP2016520422A JP2016521987A5 JP 2016521987 A5 JP2016521987 A5 JP 2016521987A5 JP 2016520422 A JP2016520422 A JP 2016520422A JP 2016520422 A JP2016520422 A JP 2016520422A JP 2016521987 A5 JP2016521987 A5 JP 2016521987A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- seq
- snp
- represented
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 227
- 125000003729 nucleotide group Chemical group 0.000 claims 227
- 108700028369 Alleles Proteins 0.000 claims 75
- 101150092117 AVPR1B gene Proteins 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 230000004797 therapeutic response Effects 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 238000002493 microarray Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000004461 rapid eye movement Effects 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- NJXZWIIMWNEOGJ-WEWKHQNJSA-N (2s,4r)-1-[(3r)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-n,n-dimethylpyrrolidine-2-carboxamide Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2[C@@](N2[C@@H](C[C@@H](O)C2)C(=O)N(C)C)(C=2C(=CC=CC=2)OC)C1=O NJXZWIIMWNEOGJ-WEWKHQNJSA-N 0.000 claims 1
- 206010002869 Anxiety symptoms Diseases 0.000 claims 1
- 101800000115 Copeptin Proteins 0.000 claims 1
- 206010054089 Depressive symptom Diseases 0.000 claims 1
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1310782.6 | 2013-06-17 | ||
| GBGB1310782.6A GB201310782D0 (en) | 2013-06-17 | 2013-06-17 | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| PCT/EP2014/062592 WO2014202541A1 (en) | 2013-06-17 | 2014-06-16 | Method for predicting a treatment response to a crhr1 antagonist and/or a v1b antagonist in a patient with depressive and/or anxiety symptoms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521987A JP2016521987A (ja) | 2016-07-28 |
| JP2016521987A5 true JP2016521987A5 (enExample) | 2017-07-06 |
| JP6689743B2 JP6689743B2 (ja) | 2020-04-28 |
Family
ID=48914695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520422A Active JP6689743B2 (ja) | 2013-06-17 | 2014-06-16 | 抑うつ症状及び不安症状の少なくとも一方を有する患者におけるバソプレッシン受容体１ｂアンタゴニストに対する治療応答を予測する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10190168B2 (enExample) |
| EP (2) | EP3623483A1 (enExample) |
| JP (1) | JP6689743B2 (enExample) |
| CA (1) | CA2914866C (enExample) |
| DK (1) | DK3011048T3 (enExample) |
| ES (1) | ES2759507T3 (enExample) |
| GB (1) | GB201310782D0 (enExample) |
| WO (1) | WO2014202541A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| AU2016240213B2 (en) * | 2015-04-02 | 2022-01-27 | HMNC Holding GmbH | Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists |
| AU2016240212B2 (en) * | 2015-04-02 | 2022-01-27 | HMNC Holding GmbH | Genetic predictors of a response to treatment with CRHR1 antagonists |
| WO2017035528A1 (en) * | 2015-08-27 | 2017-03-02 | Nantneuro, Llc | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| CN113632174B (zh) | 2019-01-23 | 2025-03-25 | 密歇根大学董事会 | 用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持 |
| WO2022200966A1 (en) * | 2021-03-23 | 2022-09-29 | Iluria Ltd. | Diagnosis and monitoring medical treatment effectivness for anxiety and depression disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0674641B1 (en) | 1992-12-17 | 1999-03-03 | Pfizer Inc. | Pyrrolopyrimidines as crf antagonists |
| HUT74464A (en) | 1993-10-12 | 1996-12-30 | Du Pont Merck Pharma | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5591588A (en) | 1994-09-20 | 1997-01-07 | Gideon Goldstein | Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| PL191271B1 (pl) | 1996-02-07 | 2006-04-28 | Neurocrine Biosciences Inc | Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna |
| EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| ATE355102T1 (de) | 2001-03-13 | 2006-03-15 | Bristol Myers Squibb Pharma Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligande |
| EP1514946A4 (en) | 2002-05-17 | 2006-06-07 | Riken | METHOD FOR DETECTING GENE POLYMORPHISM |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| EP1659121A4 (en) | 2003-08-28 | 2008-11-26 | Taisho Pharmaceutical Co Ltd | 1,3-dihydro-2H-indol-2-one derivative |
| US20050069936A1 (en) | 2003-09-26 | 2005-03-31 | Cornelius Diamond | Diagnostic markers of depression treatment and methods of use thereof |
| US20080118918A1 (en) | 2004-08-13 | 2008-05-22 | The Regents Of The University Of California | Compositions and Methods For Determining and Predicting Treatment Responses For Depression and Anxiety |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| JP2008526702A (ja) * | 2004-12-31 | 2008-07-24 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用 |
| JP5125501B2 (ja) | 2005-01-28 | 2013-01-23 | 大正製薬株式会社 | １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物 |
| BRPI0711872A2 (pt) | 2006-05-22 | 2011-12-06 | Vanda Pharmaceuticals Inc | tratamento para distúrbios depressivos |
| UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| WO2009113985A1 (en) | 2008-03-13 | 2009-09-17 | Maria Athanasiou | Genetic markers associated with response to antidepressants |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| US9644240B2 (en) * | 2009-10-22 | 2017-05-09 | Leiden University | Disease susceptibility |
| US20150278438A1 (en) | 2012-04-23 | 2015-10-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
| EP2841068B8 (en) | 2012-04-23 | 2019-03-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| GB201210686D0 (en) * | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
-
2013
- 2013-06-17 GB GBGB1310782.6A patent/GB201310782D0/en not_active Ceased
-
2014
- 2014-06-16 EP EP19190295.6A patent/EP3623483A1/en not_active Withdrawn
- 2014-06-16 DK DK14736319T patent/DK3011048T3/da active
- 2014-06-16 WO PCT/EP2014/062592 patent/WO2014202541A1/en not_active Ceased
- 2014-06-16 CA CA2914866A patent/CA2914866C/en active Active
- 2014-06-16 JP JP2016520422A patent/JP6689743B2/ja active Active
- 2014-06-16 ES ES14736319T patent/ES2759507T3/es active Active
- 2014-06-16 US US14/898,877 patent/US10190168B2/en active Active
- 2014-06-16 EP EP14736319.6A patent/EP3011048B1/en active Active
-
2018
- 2018-12-21 US US16/230,123 patent/US10837062B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521987A5 (enExample) | ||
| Zhang et al. | Germline mutations in CDH23, encoding cadherin-related 23, are associated with both familial and sporadic pituitary adenomas | |
| Abicht et al. | Congenital myasthenic syndromes: Achievements and limitations of phenotype‐guided gene‐after‐gene sequencing in diagnostic practice: A study of 680 patients | |
| Tripolszki et al. | Comprehensive genetic analysis of a Hungarian amyotrophic lateral sclerosis cohort | |
| Saxena et al. | Association of IL-6, TNF-α and IL-10 gene polymorphisms with type 2 diabetes mellitus | |
| Rosentul et al. | Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis | |
| Yang et al. | Genetic susceptibility to lung cancer and co-morbidities | |
| Bachmann-Gagescu et al. | Recurrent 200-kb deletions of 16p11. 2 that include the SH2B1 gene are associated with developmental delay and obesity | |
| Olbrich et al. | Recessive HYDIN mutations cause primary ciliary dyskinesia without randomization of left-right body asymmetry | |
| Vulto-van Silfhout et al. | Mutations affecting the SAND domain of DEAF1 cause intellectual disability with severe speech impairment and behavioral problems | |
| JP2010507388A5 (enExample) | ||
| Liu et al. | Is sudden unexplained nocturnal death syndrome in Southern China a cardiac sodium channel dysfunction disorder? | |
| JP2008546403A5 (enExample) | ||
| JP2011530306A5 (enExample) | ||
| NZ598009A (en) | Genetic markers associated with risk of diabetes mellitus | |
| Kim et al. | Gene-based copy number variation study reveals a microdeletion at 12q24 that influences height in the Korean population | |
| ES2759507T3 (es) | Método para predecir una respuesta de tratamiento a un antagonista de V1B en un paciente con síntomas depresivos y/o de ansiedad | |
| Faria et al. | Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population | |
| JP2010510804A5 (enExample) | ||
| Fidler et al. | Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis | |
| Mitra et al. | GADD45a promoter regulation by a functional genetic variant associated with acute lung injury | |
| Vyshkina et al. | Association of haplotypes in the β-chemokine locus with multiple sclerosis | |
| Schneider et al. | Identification of disrupted AUTS2 and EPHA6 genes by array painting in a patient carrying a de novo balanced translocation t (3; 7) with intellectual disability and neurodevelopment disorder | |
| Guo et al. | Exome sequencing identifies a novel MYH7 p. G407C mutation responsible for familial hypertrophic cardiomyopathy | |
| Haunstrup et al. | Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation |